TheraRadar
← Back
Data updated: Jun 28, 2026

YABAO PHARM

Generics

YABAO PHARM is a generic drug manufacturer focused on Metabolic, Oncology.

2006
Since
4
Drugs
-
Trials
0
New Drugs (2yr)

YABAO PHARM's Key Drugs

YABAO PHARM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

YABAO PHARM's Recent FDA Approvals

New NDA/BLA approvals for YABAO PHARM over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

YABAO PHARM's Therapeutic Areas

YABAO PHARM's approved drugs and pipeline span 2 therapeutic areas, led by Metabolic and Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Metabolic 71%
1 drugs Phase 2: 1 Phase 1: 7
Oncology 29%
1 drugs

YABAO PHARM's Top Competitors

YABAO PHARM's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

YABAO PHARM Pipeline Snapshot

YABAO PHARM has 8 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 7 Phase 1.

0
Phase 3
1
Phase 2
7
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Metabolic pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling